Amgen Inc. Files SEC Form 4 Disclosure

According to a recent U.S. Securities and Exchange Commission filing, Amgen Inc. disclosed information regarding the company's director, officer, or owner of more than 10% of a class of equity securities registered under Section 12 of the '34 Act. The filing, made on November 10, 2022, provides details on the company's beneficial ownership of securities, including purchases and sales of equity securities. The Amgen Inc. filing is a requirement under the Securities and Exchange Act of 1934, which mandates publicly-traded companies to disclose such information to the SEC.

Key Takeaways:

• The filing, made on November 10, 2022, is a required disclosure under the Securities and Exchange Act of 1934 for publicly-traded companies.
• The SEC filing, Form 4, is a statement of ownership regarding Amgen Inc.'s equity securities, submitted by one of the company's directors, officers, or owners of more than 10% of a class of equity securities.
• The company is required to disclose information on purchases and sales of equity securities, as well as their relationship with the company.
• Amgen Inc.'s SIC code is 2836, indicative of a biological products manufacturer (no diagnostic substances).
• The SEC file number for this filing is 0001127602-22-025334.
• The contact information for Amgen Inc. is One Amgen Center Drive, Thousand Oaks, CA 91320, with a phone number of (805) 447-1000.

Statistics:

• The filing was made on November 10, 2022, under the SEC file number 0001127602-22-025334.
• The SIC code for Amgen Inc. is 2836, indicating biological products (no diagnostic substances).
• The company's address is registered as One Amgen Center Drive, Thousand Oaks, CA 91320.

Sources:

• NewsRx LLC, 2022 NOV 30, NewsRx: "Amgen Inc. Files SEC Form 4 Disclosure"
• Securities and Exchange Commission, U.S. Securities and Exchange Commission filing, Form 4, Amgen Inc., 0001127602-22-025334
• Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, (805) 447-1000